Rape
Brassica napus rapeseed canola crop agriculture
| Feature | Rapeseed | Canola |
|---|---|---|
| Erucic acid | High (>2%) | Low (<2%) |
| Glucosinolates | High | Low |
| Primary use | Industrial/biofuel | Edible food/feed |
| Registered name | Traditional | Canada, 1979 |
Rape in sexual assault in fmt
| Location | Mechanism |
|---|---|
| Mouth, lips, throat | Preventing cries for help |
| Wrists, arms | Restraint |
| Back | Pinning victim to hard ground |
| Inner thighs, knees | Forcing legs apart |
| Breasts | Rough handling; bite marks (love bites) |
| Sample | Method | Purpose |
|---|---|---|
| Low vaginal swab | Before digital exam, via speculum | Spermatozoa, DNA |
| High vaginal swab | Under direct vision via speculum | Spermatozoa, DNA |
| Cervical mucus swab | >48 hours after assault | Best site for late sperm recovery |
| Posterior fornix aspirate | 10 ml normal saline instilled, then aspirated | Motile spermatozoa |
| Seminal stain swabs | Cotton swab moistened with saline, air-dried | Acid phosphatase, DNA |
| Oral/rectal swabs | If oral or rectal contact occurred | Gonorrhoea culture, spermatozoa |
| Bite mark swabs | Swab of bite area | Saliva, blood group typing |
| Fingernail clippings | Forceps, sealed container | Trace evidence, DNA of assailant |
| Blood | - | Grouping, alcohol, drugs, VDRL, T-cells (HIV) |
| Pubic hair | 15-20 hairs pulled with forceps | Comparison with accused |
| Urine | - | Drugs, pregnancy |
Find recent clinical guidelines for post-rape STD prophylaxis and pregnancy prevention
sexual assault STI prophylaxis guidelines
sexual assault emergency contraception HIV PEP prophylaxis
sexual assault HIV post-exposure prophylaxis management
CDC 2021 guidelines sexual assault STI prophylaxis emergency contraception
sexual assault STI prophylaxis HIV PEP emergency contraception gonorrhea chlamydia
CDC sexual assault STI treatment guidelines 2021 prophylaxis regimens azithromycin doxycycline ceftriaxone metronidazole HIV PEP
sexual assault STI prophylaxis HIV PEP hepatitis B vaccination emergency contraception follow-up schedule
Primary source: CDC STI Treatment Guidelines, 2021 (MMWR Vol. 70, No. 4) - current standard of care.
| STI | Risk (%) |
|---|---|
| Gonorrhea | 6-18 |
| Chlamydia | 4-17 |
| Trichomonas | ~12 |
| Bacterial vaginosis | ~19 |
| Syphilis | 0.5-3 |
| HIV | <1 |
Note on doxycycline: A negative pregnancy test is required before prescribing doxycycline or tetracycline (contraindicated in pregnancy). In pregnant patients, use erythromycin as an alternative for chlamydia coverage. Metronidazole can cause nausea and vomiting - stagger administration by a few hours if given alongside emergency contraception to avoid vomiting affecting EC efficacy.
| Method | Timing | Efficacy | Notes |
|---|---|---|---|
| Copper IUD (Cu-IUD) | ≤5 days post-assault | ~99% | Most effective; also provides ongoing contraception. Caution: do NOT insert if patient has untreated gonorrhea, chlamydia, or purulent cervicitis (Category 4) |
| Ulipristal acetate (UPA) | ≤5 days (120 hrs) | ~85% | Prescription required; may be more effective than LNG at 72-120 hrs |
| Levonorgestrel (LNG) | ≤3 days (72 hrs); some efficacy to 5 days | ~75-89% | OTC; start ASAP |
| Combined estrogen/progestin pill (Yuzpe method) | ≤72 hrs | ~57-75% | More side effects; rarely used now |
CDC U.S. MEC classification for sexual assault: Category 2 for most ECPs (benefits outweigh risks), noting that routine presumptive treatment for chlamydia, gonorrhea, and trichomoniasis should also be initiated. Cu-IUD is Category 1 unless concurrent STI.
| Timepoint | Action |
|---|---|
| <1 week (early) | Discuss initial test results, assess PEP adherence/side effects, adjust regimen if needed, provide any vaccines not given initially |
| 1-2 weeks | Repeat STI testing if initial tests negative and treatment not given |
| 1-2 months | Second hepatitis B vaccine (if initiated), repeat HIV test, RPR for syphilis |
| 4-6 months | Third hepatitis B vaccine, final HIV test, RPR repeat |
POST-RAPE PROPHYLAXIS CHECKLIST
□ Pregnancy test (beta-hCG)
□ EC - LNG (≤72h) / UPA (≤120h) / Cu-IUD (≤5 days, most effective)
STI PROPHYLAXIS
□ Ceftriaxone 500 mg IM stat (1 g if ≥150 kg)
□ Doxycycline 100 mg PO BD × 7 days (if not pregnant)
□ Metronidazole 500 mg PO BD × 7 days
HIV PEP (if indicated - within 72 hours)
□ TDF/FTC + raltegravir or dolutegravir × 28 days
□ Hotline: 1-888-448-4911
VACCINATIONS
□ Hepatitis B vaccine (dose 1) if unvaccinated
□ HPV vaccine (ages 9-26) if not completed
□ HBIg if assailant known HBsAg+ and survivor non-immune
FOLLOW-UP
□ <1 week: PEP check, test results
□ 1-2 months: Hep B dose 2, HIV retest
□ 4-6 months: Hep B dose 3, final HIV test